Black Creek Investment Management Inc. Sells 788,830 Shares of Grifols, S.A. $GRFS

Black Creek Investment Management Inc. decreased its holdings in Grifols, S.A. (NASDAQ:GRFS) by 7.9% in the fourth quarter, Holdings Channel reports. The firm owned 9,257,127 shares of the biotechnology company’s stock after selling 788,830 shares during the quarter. Grifols accounts for about 4.3% of Black Creek Investment Management Inc.’s portfolio, making the stock its 11th biggest position. Black Creek Investment Management Inc.’s holdings in Grifols were worth $86,554,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of GRFS. Bank of Montreal Can increased its holdings in shares of Grifols by 3,205.1% in the 3rd quarter. Bank of Montreal Can now owns 3,013,723 shares of the biotechnology company’s stock worth $30,017,000 after purchasing an additional 2,922,540 shares in the last quarter. Arrowstreet Capital Limited Partnership boosted its stake in shares of Grifols by 383.7% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 2,800,645 shares of the biotechnology company’s stock worth $27,894,000 after buying an additional 2,221,633 shares during the last quarter. Norges Bank purchased a new position in shares of Grifols in the 4th quarter worth $18,139,000. Brandes Investment Partners LP boosted its stake in shares of Grifols by 6.3% in the 4th quarter. Brandes Investment Partners LP now owns 30,954,223 shares of the biotechnology company’s stock worth $289,422,000 after buying an additional 1,838,727 shares during the last quarter. Finally, Capital World Investors boosted its stake in shares of Grifols by 5.9% in the 3rd quarter. Capital World Investors now owns 22,926,140 shares of the biotechnology company’s stock worth $228,344,000 after buying an additional 1,273,391 shares during the last quarter.

Analysts Set New Price Targets

A number of research firms have recently issued reports on GRFS. Wall Street Zen downgraded Grifols from a “buy” rating to a “hold” rating in a research note on Monday, May 18th. Weiss Ratings upgraded Grifols from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Friday, May 8th. Finally, Zacks Research downgraded Grifols from a “hold” rating to a “strong sell” rating in a research note on Friday, May 8th. Three analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Reduce” and an average price target of $10.00.

Grifols Price Performance

NASDAQ GRFS opened at $7.64 on Friday. The company has a market capitalization of $5.20 billion, a PE ratio of 40.21, a price-to-earnings-growth ratio of 0.30 and a beta of 0.65. The company has a debt-to-equity ratio of 1.16, a quick ratio of 0.85 and a current ratio of 2.47. The business’s fifty day moving average is $8.01 and its 200 day moving average is $8.56. Grifols, S.A. has a fifty-two week low of $7.26 and a fifty-two week high of $11.14.

Grifols (NASDAQ:GRFS) last released its earnings results on Saturday, February 14th. The biotechnology company reported $0.38 earnings per share for the quarter. The company had revenue of $2.32 billion for the quarter. Grifols had a return on equity of 6.21% and a net margin of 5.54%. Sell-side analysts predict that Grifols, S.A. will post 1.06 earnings per share for the current year.

Grifols Profile

Grifols, Inc (NASDAQ: GRFS) is a global healthcare company specializing in the development, manufacture and marketing of plasma-derived medicines, diagnostic systems and hospital supplies. With a core focus on immunotherapy and transfusion medicine, the company harnesses human plasma proteins to create therapies that treat a wide range of bleeding disorders, immunodeficiencies and neurological conditions. Grifols also supplies reagents and diagnostic instruments for transfusion centers and clinical laboratories, alongside intravenous solutions and medical devices for hospital use.

The company operates three main business units.